Symphogen
Manufacturing · Denmark · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Pederstrupvej 93, Ballerup, Capital Regi...Phone Number
+45 45265050Website
www.symphogen.comRevenue
$44.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Symphogen
Symphogen is a private biopharmaceutical company leading the field of antibody mixtures for therapeutic use in oncology and other significant diseases. Symphogen is dedicated to bringing novel antibody products to the market, creating optimally selected antibody mixtures in a single drug product. The company has collaborations for the development of antibody therapeutics in immuno-oncology with the Shire and the infectious disease area with Genentech. Symphogen was founded in 2000 and is headquartered in Denmark.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Symphogen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Symphogen recently announced quarterly report
Symphogen, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Symphogen is spiking on competitors!
Click to see if Symphogen had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Symphogen
Funding: Get notified immidiatlly once Symphogen has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Symphogen launches new products
Check if Symphogen has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Symphogen
Find 2 more new buyers
Company Profile Activity
Activity Insights
Symphogen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Symphogen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Symphogen.
Symphogen financials insights
Gather financial insights about Symphogen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Private Equity
$112.3M
2015
Debt
$76.6M
Symphogen Tech Stack
A closer look at the technologies used by Symphogen
Symphogen News & Media
Servier Completes the Acquisition of Symphogen
PARIS, June 4, 2020 /PRNewswire/ -- Servier, an independent international pharmaceutical company, today announced that it has completed the acquisition of Symphogen A/S. Symphogen will now function as Servier's antibody center of excellence across multiple therapeutic areas, including...Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline
Paris (France), Copenhagen (Denmark), April 3, 2020 – Servier, an independent international pharmaceutical company, announced today that it has entered into a definitive agreement with the owners of Symphogen A/S, a leader in therapeutic antibody discovery, to acquire 100% of Symphogen’s share capital. The acquisition, the result of a process that has been underway for several months now, will strengthen Servier’s antibody capabilities and ensure that Symphogen’s antibody discovery and early-devSymphogen publishes discovery and pre-clinical data on first chicken-derived antibody to enter human clinical trials
Sym021 a novel anti-PD1 compound currently in Phase 1 clinical trialsSymphogen announces new capital raise and explores strategic options
Copenhagen, 15 May 2019 – Today, Symphogen called for an ordinary shareholders meeting to be held on 29 May 2019. At the meeting, Symphogen’s Board of Directors will propose to raise new capital through a pre-emptive issue of new preferred shares and warrants to existing shareholders.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Symphogen
Sign Up For FreeTo access detailed company insights
Symphogen is a private biopharmaceutical company leading the field of antibody mixtures for therapeutic use in oncology and other significant diseases. Symphogen is dedicated to bringing novel antibody products to the market, creating optimally selected antibody mixtures in a single drug product. The company has collaborations for the development o... Read More
